The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
The company, which has been hit by the slow-down in the growth of smartphone sales, said 95.5% of the shares on offer in its recent underwritten rights issue, priced at 85p a share, were taken up by shareholders.
£1.35 looks like a good strong share but a bit slow however still pleased with progress. BT
Sorry if wrong took it from rns. Cash(4) � � c. 13 � 9.7 Plus its unaudited also. BT
Cash in bank but cash burn of £1.6 million per month means 6 months which is plenty of time to get some cash in for orders. GL BT
Hardman Research: CARB-X - new strategic collaboration CARB-X - new strategic collaboration - Although Redx has only been operational since late-2010, it has already discovered several valuable drug candidates, the first of which is about to begin clinical trials. Although management is focusing resources on the clinical-stage projects, it will also be seeking partners to advance its other assets, thereby maximising shareholder value. Redx has announced the first such collaboration with CARB-X to progress its new class of antibiotics against hard to treat Gram-negative bacteria. Following a competitive process, Redx has been awarded a grant of $1m over 18 months, with the potential to receive further development milestones. Please click here for the full report: http://hardmanandco.com/docs/default-source/company-docs/redx-pharma--documents/redx-gram-negative-grant-3rd-april-2017.pdf To contact us: Hardman & Co 11/12 Tokenhouse Yard London EC2R 7AS Contacts: Dr Martin Hall mh@hardmanandco.com Dr Dorothea Hill dmh@hardmanandco.com Dr Gregoire Pave gp@hardmanabdco.com Telephone: +44 20 7929 3399 Follow us on Twitter @HardmanandCo www.hardmanandco.com About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
BT
Well I seek on points elsewhere and have to move quick. I decided the low volume indicated early was a point to jump. But will be back. Got in where I wanted split over 2 sticks lower than where I was before I came here. All maths Good fun BT
That's me gone cheers Back soon BT
Drugs are always risky!!
Are you?
As you a Dandee Don's fan as in Aberdeen? Just wondering as you seem negative and pretty used to losing? BT
Why do u hate the company. Are you the local basher? God well I need to take ur advice then coz ur amazing. It's your % you want mate so set your stall take yours or sit and wait til you can say I told you so and everyone's gone anyway with their profit %. :-) BT
Boost when these drugs come on. Thing is there's so many and most biotechnology stocks focus on 1 so if it fails it's game over but Redx has numerous so the results could be huge and very low risk of every one being a dud. My new hot stock BT
Funded. No debt. $1 million handed to us out of only 11 in 160 odd applicants. Share funds raised at 37p undervalued stock right now. All good BT
Look for big boost up BT
$1million GL BT
Delay in spud BT
Out
To be honest that's not a good rns Pump before dump obviously GL BT